metformin has been researched along with Disbacteriosis in 24 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 5.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| " The effect of HFD on maternal rats was alleviated by prenatal metformin, which also ameliorated inflammation and apoptosis in the fetal liver and intestines." | 4.02 | Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. ( Hou, CY; Huang, LT; Huang, SW; Lin, IC; Ou, YC; Sheen, JM; Tain, YL; Tang, KS; Tiao, MM; Tsai, CC; Yu, HR, 2021) |
| "PSO and metformin had the beneficial effect on attenuating gut inflammation and metabolic disturbance in obese-insulin resistance." | 4.02 | Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats. ( Chattipakorn, N; Chattipakorn, SC; Kangwan, N; Kongkaew, A; Pintha, K; Pratchayasakul, W, 2021) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite generated from its dietary precursors such as choline, has been identified as an independent risk factor for atherosclerosis." | 4.02 | Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality. ( Du, Y; Hong, B; Li, X; Su, C; Wang, L; Yang, Y; Zhang, X, 2021) |
| "Metformin is a major treatment for type 2 diabetes." | 3.01 | Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects. ( Cho, JY; Chung, JY; Ji, SC; Kim, AH; Kim, E; Lee, Y; Yu, KS, 2021) |
| "Metformin is a widely used first-line drug for treatment of type 2 diabetes." | 2.87 | Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. ( Elbere, I; Fridmanis, D; Gudra, D; Kalnina, I; Klovins, J; Konrade, I; Pirags, V; Radovica-Spalvina, I; Sekace, K; Silamikelis, I; Zaharenko, L, 2018) |
| "Strategies to prevent and treat type 2 diabetes through manipulation of the gut microbiota are being developed." | 2.61 | Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes. ( Caesar, R, 2019) |
| "Gut dysbiosis was recently associated with the occurrence of type 2 diabetes (T2D)." | 2.58 | Metformin: old friend, new ways of action-implication of the gut microbiome? ( Delzenne, NM; Hiel, S; Rodriguez, J, 2018) |
| "Gut microbiota dysbiosis is critical in the etiology of polycystic ovary syndrome (PCOS)." | 1.72 | Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells. ( Chen, P; Huang, J; Liang, Q; Liang, X; Liu, J; Wu, T; Xiang, Y; Zeng, H; Zeng, Y; Zhou, C, 2022) |
| " As stable coronary artery disease (SCAD) patients combined with type 2 diabetes have significantly increased risk for cardiac event, we focused on elucidating the role of microbiota affecting cardiometabolic disease development." | 1.62 | Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis. ( Feng, S; Liang, L; Liu, H; Tian, R; Wang, H; Wang, Y; Xing, H; Xu, H; Zhang, S, 2021) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 1.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Gut dysbiosis has been associated with several disease outcomes including diabetes in human populations." | 1.56 | Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans. ( Adebamowo, C; Adebamowo, SN; Adeyemo, A; Doumatey, AP; Lei, L; Rotimi, CN; Zhou, J, 2020) |
| "Metformin is a widely used hypoglycemic agent, while resistant starch (RS) is a novel dietary fiber that emerges as a nutritional strategy for metabolic disease." | 1.56 | A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. ( Li, R; Luo, L; Ma, S; Qiao, S; Wang, N; Wang, X; Wu, J; Xu, W; Zhang, C; Zhang, Y; Zhao, B, 2020) |
| "Metformin is a safe, effective and inexpensive generic medication favouring weight loss, recommended as initial treatment of type 2 diabetes by the American Diabetes Association." | 1.40 | A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. ( Greenway, F; Heiman, M; Wang, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 17 (70.83) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SW | 1 |
| Ou, YC | 1 |
| Tang, KS | 1 |
| Yu, HR | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Lin, IC | 1 |
| Sheen, JM | 1 |
| Hou, CY | 1 |
| Tsai, CC | 1 |
| Tiao, MM | 1 |
| Kangwan, N | 1 |
| Pratchayasakul, W | 1 |
| Kongkaew, A | 1 |
| Pintha, K | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Huang, J | 1 |
| Chen, P | 1 |
| Xiang, Y | 1 |
| Liang, Q | 1 |
| Wu, T | 1 |
| Liu, J | 1 |
| Zeng, Y | 1 |
| Zeng, H | 1 |
| Liang, X | 1 |
| Zhou, C | 1 |
| Zaongo, SD | 1 |
| Chen, Y | 5 |
| Fu, GL | 1 |
| Meng, QY | 1 |
| Xin, JZ | 1 |
| Liu, JH | 1 |
| Dang, W | 1 |
| Lu, HL | 1 |
| Adeshirlarijaney, A | 1 |
| Gewirtz, AT | 1 |
| Ahmadi, S | 1 |
| Razazan, A | 1 |
| Nagpal, R | 1 |
| Jain, S | 1 |
| Wang, B | 1 |
| Mishra, SP | 1 |
| Wang, S | 2 |
| Justice, J | 1 |
| Ding, J | 1 |
| McClain, DA | 1 |
| Kritchevsky, SB | 1 |
| Kitzman, D | 1 |
| Yadav, H | 1 |
| Ouyang, J | 2 |
| Isnard, S | 2 |
| Lin, J | 2 |
| Fombuena, B | 2 |
| Marette, A | 2 |
| Routy, B | 2 |
| Routy, JP | 2 |
| Doumatey, AP | 1 |
| Adeyemo, A | 1 |
| Zhou, J | 1 |
| Lei, L | 1 |
| Adebamowo, SN | 1 |
| Adebamowo, C | 1 |
| Rotimi, CN | 1 |
| Peng, X | 1 |
| Messaoudene, M | 1 |
| Zhang, C | 1 |
| Ma, S | 1 |
| Wu, J | 1 |
| Luo, L | 1 |
| Qiao, S | 1 |
| Li, R | 1 |
| Xu, W | 1 |
| Wang, N | 1 |
| Zhao, B | 1 |
| Wang, X | 2 |
| Zhang, Y | 1 |
| Tian, R | 1 |
| Liu, H | 1 |
| Feng, S | 1 |
| Wang, H | 2 |
| Wang, Y | 2 |
| Liang, L | 1 |
| Xu, H | 1 |
| Xing, H | 1 |
| Zhang, S | 1 |
| Li, P | 1 |
| Lu, B | 1 |
| Gong, J | 1 |
| Li, L | 1 |
| Chen, G | 1 |
| Zhang, J | 1 |
| Tian, X | 1 |
| Han, B | 1 |
| Guo, Y | 1 |
| Xie, Z | 1 |
| Liao, Q | 1 |
| Moore, E | 1 |
| Reynolds, JA | 1 |
| Davidson, A | 1 |
| Gallucci, S | 1 |
| Morel, L | 1 |
| Rao, DA | 1 |
| Young, HA | 1 |
| Putterman, C | 1 |
| Kim, E | 1 |
| Kim, AH | 1 |
| Lee, Y | 1 |
| Ji, SC | 1 |
| Cho, JY | 1 |
| Yu, KS | 1 |
| Chung, JY | 1 |
| Yan, N | 1 |
| Wang, L | 2 |
| Li, Y | 1 |
| Wang, T | 1 |
| Yang, L | 1 |
| Yan, R | 1 |
| Jia, S | 1 |
| Su, C | 1 |
| Li, X | 1 |
| Yang, Y | 1 |
| Du, Y | 1 |
| Zhang, X | 1 |
| Hong, B | 1 |
| Rodriguez, J | 1 |
| Hiel, S | 1 |
| Delzenne, NM | 1 |
| Elbere, I | 1 |
| Kalnina, I | 1 |
| Silamikelis, I | 1 |
| Konrade, I | 1 |
| Zaharenko, L | 1 |
| Sekace, K | 1 |
| Radovica-Spalvina, I | 1 |
| Fridmanis, D | 1 |
| Gudra, D | 1 |
| Pirags, V | 1 |
| Klovins, J | 1 |
| Xourgia, E | 1 |
| Papazafiropoulou, A | 1 |
| Papanas, N | 1 |
| Melidonis, A | 1 |
| Caesar, R | 1 |
| Greenway, F | 1 |
| Heiman, M | 1 |
| Kim, T | 1 |
| Holleman, CL | 1 |
| Ptacek, T | 1 |
| Morrow, CD | 1 |
| Habegger, KM | 1 |
| Pedersen, C | 1 |
| Gallagher, E | 1 |
| Horton, F | 1 |
| Ellis, RJ | 1 |
| Ijaz, UZ | 1 |
| Wu, H | 1 |
| Jaiyeola, E | 1 |
| Diribe, O | 1 |
| Duparc, T | 1 |
| Cani, PD | 1 |
| Gibson, GR | 1 |
| Hinton, P | 1 |
| Wright, J | 1 |
| La Ragione, R | 1 |
| Robertson, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial for Analysis of Intestinal Microbiome Affecting Pharmacokinetics, Pharmacodynamics, and Safety of Metformin in Healthy Volunteers[NCT03809260] | 20 participants (Actual) | Interventional | 2018-12-01 | Completed | |||
| The Effect of Multi-strain Probiotics on Gastrointestinal Symptoms in Patients With Type 2 Diabetes and Metformin Intolerance. A 32-week Prospective, Single Center, Randomized, Placebo Controlled, Cross-over Clinical Trial.[NCT04089280] | 37 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for metformin and Disbacteriosis
| Article | Year |
|---|---|
Metformin may be a viable adjunctive therapeutic option to potentially enhance immune reconstitution in HIV-positive immunological non-responders.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dysbiosis; | 2023 |
Metformin effect on gut microbiota: insights for HIV-related inflammation.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Disease Models, Animal; Dysbiosis; Gastrointes | 2020 |
The Bacterium
Topics: Akkermansia; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Dysbiosis; Gram-Negative Bacterial | 2020 |
Metformin: old friend, new ways of action-implication of the gut microbiome?
Topics: Animals; Bacteria; Blood Glucose; Diabetes Mellitus, Type 2; Dysbiosis; Fatty Acids, Volatile; Gastr | 2018 |
Anti-diabetic treatment leads to changes in gut microbiome.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase | 2019 |
Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Diet Therapy; Dietary Fiber; Dysbiosis; Fecal Microbiota Transplantation; | 2019 |
3 trials available for metformin and Disbacteriosis
| Article | Year |
|---|---|
Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Interactions; Dysbiosis; Enterobacter; Faecalibacterium; Fece | 2021 |
Association of metformin administration with gut microbiome dysbiosis in healthy volunteers.
Topics: Adult; Bacteria; Clostridiaceae; DNA, Bacterial; DNA, Ribosomal; Drug Administration Schedule; Dysbi | 2018 |
Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Dysbiosis; | 2016 |
15 other studies available for metformin and Disbacteriosis
| Article | Year |
|---|---|
Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Diet, High-Fat; Disease Models, Animal; Drinking Water; Dy | 2021 |
Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats.
Topics: alpha-Linolenic Acid; Animals; Blotting, Western; Diet, High-Fat; Dysbiosis; Gastrointestinal Microb | 2021 |
Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells.
Topics: Animals; Apoptosis; Dehydroepiandrosterone; Disulfiram; DNA, Ribosomal; Dysbiosis; Estrogens; Female | 2022 |
Metformin exposure altered intestinal microbiota composition and metabolites in amphibian larvae.
Topics: Animals; Anura; Dysbiosis; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Larva; Metformi | 2023 |
Considering gut microbiota in treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fiber; Dysbiosis; Gastrointestinal Microbiome; Humans; H | 2020 |
Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis.
Topics: Aging; Animals; Cognition; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Micro | 2020 |
Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans.
Topics: Actinobacteria; Bacteroidetes; Black People; Case-Control Studies; Diabetes Mellitus, Type 2; Dysbio | 2020 |
A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
Topics: Animals; Bacteria; Biomarkers; Blood Glucose; Chromatography, Liquid; Diabetes Mellitus, Experimenta | 2020 |
Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis.
Topics: Aged; Bacteria; Biomarkers; Case-Control Studies; Clostridiales; Coronary Artery Disease; Diabetes M | 2021 |
Chickpea Extract Ameliorates Metabolic Syndrome Symptoms via Restoring Intestinal Ecology and Metabolic Profile in Type 2 Diabetic Rats.
Topics: Animals; Cicer; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dysbiosi | 2021 |
Promise and complexity of lupus mouse models.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Congresses as Topic; Disease Models, Animal; Drug | 2021 |
Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Dysbiosis; Fatty Acids, Volat | 2021 |
Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality.
Topics: Akkermansia; Animals; Atherosclerosis; Bifidobacterium; Choline; Diabetes Mellitus, Type 2; Diet; Dy | 2021 |
A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report.
Topics: Adult; Antioxidants; beta-Glucans; Blood Glucose; Blueberry Plants; Diabetes Mellitus, Type 2; Dieta | 2014 |
Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Dysbiosis; Gastric Bypass; Gas | 2017 |